Cubist seeks European review of new antibiotic


European regulators will review a Cubist Pharmaceuticals Inc. application to sell a new antibiotic treating urinary tract and intra-abdominal infections in the European Union.

The biotech company, based in Lexington, said Friday that its experimental antibiotic, called ceftolozane/tazobactam, has been accepted for review by the European Medicines Agency, an arm of the European Commission that rules on new drug applications. Cubist is expecting a decision next year on the drug, which fights infections caused by Gram-negative bacteria.

Cubist has also applied for approval of ceftolozane/tazobactam by the Food and Drug Administration and is expecting the US regulatory agency to make a ruling by Dec. 21.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of